- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Autolus Therapeutics Ltd (AUTL)
Autolus Therapeutics Ltd stock price live, this page displays NASDAQ AUTL stock exchange data. View the AUTL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Autolus Therapeutics Ltd real time stock price chart below.
What Is the Autolus Therapeutics Ltd Stock Price Today?
The Autolus Therapeutics Ltd stock price today is 2.590.
What Is the Stock Symbol for Autolus Therapeutics Ltd?
The stock symbol for Autolus Therapeutics Ltd is ""AUTL.""
What Stock Exchange Does Autolus Therapeutics Ltd Trade On?
Autolus Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Autolus Therapeutics Ltd a Good Stock to Buy?
Determining whether Autolus Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUTL quote. (ISIN: US05280R1005)
What Is the Autolus Therapeutics Ltd Stock Price Today?
The Autolus Therapeutics Ltd stock price today is 2.590.
What Is the Stock Symbol for Autolus Therapeutics Ltd?
The stock symbol for Autolus Therapeutics Ltd is ""AUTL.""
What Stock Exchange Does Autolus Therapeutics Ltd Trade On?
Autolus Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Autolus Therapeutics Ltd a Good Stock to Buy?
Determining whether Autolus Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUTL quote. (ISIN: US05280R1005)
2.590
-0.090(-3.36%)
Real-time Data·
Fair Value
An estimate of a Autolus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.570
2.700
52 wk Range
1.105
5.000
AUTL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 7 days
More Info
Fair Value
An estimate of a Autolus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5702.700
52 wk Range
1.1055.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AUTL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Autolus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
9.856
Upside
+280.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Autolus Therapeutics Ltd Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics Ltd Earnings Call Summary for Q4/2024
- Net loss increased to $220.7M in 2024, up from $208.4M in 2023; cash reserves rose to $588M due to BioNTech collaboration and equity financing
- FDA approved Ocassol without REMS program; company plans to expand to 60 centers by year-end, targeting EU and UK regulatory submissions in 2025
- Stock price dipped 0.26% to $1.94 post-earnings; market cap at $518.67M with strong liquidity but rapid cash burn noted by InvestingPro
- No 2025 sales guidance provided; CEO and CFO express confidence in launch and commercialization plans for obiCELL
- Analysts focused on outpatient administration potential and manufacturing consistency during Q&A, crucial for planned market expansion
Last Updated: 20/03/2025, 14:52
Read Full TranscriptCompare AUTL to Peers and Sector
Metrics to compare | AUTL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUTLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −5.7x | −0.5x | |
PEG Ratio | −0.12 | 0.00 | 0.00 | |
Price/Book | 1.9x | 4.0x | 2.6x | |
Price / LTM Sales | 77.8x | 9.3x | 3.2x | |
Upside (Analyst Target) | 273.1% | 151.6% | 41.9% | |
Fair Value Upside | Unlock | 8.9% | 4.3% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.856
(+280.52% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.26 / -0.26
Revenue / Forecast
2.10M / 1.42M
People Also Watch
FAQ
What Stock Exchange Does Autolus Therapeutics Trade On?
Autolus Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Autolus Therapeutics?
The stock symbol for Autolus Therapeutics is "AUTL."
What Is the Autolus Therapeutics Market Cap?
As of today, Autolus Therapeutics market cap is 690.64M.
What Is Autolus Therapeutics's Earnings Per Share (TTM)?
The Autolus Therapeutics EPS (TTM) is -0.89.
When Is the Next Autolus Therapeutics Earnings Date?
Autolus Therapeutics will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is AUTL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Autolus Therapeutics Stock Split?
Autolus Therapeutics has split 0 times.
How Many Employees Does Autolus Therapeutics Have?
Autolus Therapeutics has 649 employees.
What is the current trading status of Autolus Therapeutics (AUTL)?
As of 24 Jul 2025, Autolus Therapeutics (AUTL) is trading at a price of 2.59, with a previous close of 2.68. The stock has fluctuated within a day range of 2.57 to 2.70, while its 52-week range spans from 1.11 to 5.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.